Integrated drug discovery contract research organization (CRO) Sygnature Discovery has invested £3.75 million in an Azenta compound management storage system that can also provide customer libraries.
It was announced today (October 31), that the US Food and Drug Administration (FDA) has granted permission to proceed with clinical investigations of small molecule treatment, roginolisib.
In the midst of International Gaucher Disease Awareness Month, GlobalData has highlighted a 'critical' issue within the Gaucher disease landscape: the significant lack of neuronopathic therapies.
She has a proven track record of leading and mentoring start-ups in the biotechnology field, with her proven abilities in investment and portfolio management, investments, risk management, and business strategy development, Maria is a go-to expert in...
Clinical stage pharma company PharmaKure believe their combined drug targeting amyloid deposits associated with Alzheimer’s Disease can bring quality of life to patients.
The treatment of rare brain disease, progressive supranuclear palsy (PSP), that has no disease modifying therapies, has been given a glimmer of hope by Amylyx Pharmaceuticals.
Feedback has been submitted to the US Food and Drug Administration (FDA) with guidelines intended for sponsors of clinical trials related to psychedelic compounds.
Matteo Lai was part of a panel at DPharm in Boston this year, it was called working together to accelerate the adoption of digital biomarkers in clinical trials.
Researchers at the UK Dementia Research Institute have developed a new form of deep brain stimulation that does not require surgery and could provide an alternative treatment option for debilitating brain diseases such as Alzheimer’s.
Dave Hine is the senior director of sales engineering at Greenphire. He has been reflecting on his time at DPharm and the collaborative approach to life sciences.
A collaboration has been formed between the US pharmacy chain Walgreens and the Cardiovascular Research Foundation (CRF) to measure how prevalent valvular heart disease (VHD) is among older Americans.
Clerkenwell Health is partnering with Transcend Therapeutics to trial the use of methylone in patients with severe post-traumatic stress disorder (PTSD).
Physics-powered GenAI Biotech, Gero, announced yesterday (October 18) that it had closed a $6 million series A extension round with funding from Melnicheck Investments and other investors.
The Gen AI revolution promises to redefine various industries, with the life sciences sector at the forefront of this transformation. OSP had the chance to speak to Tarun Mathur, CEO at Indegene, who was keen to allay many of the fears those in the industry...
Emma Harvey is global head of medical affairs at F2G Ltd, a UK and Austria based biotech where she is responsible for the global medical and commercial strategies for a novel antifungal drug for serious systemic infections, in clinical development.
IFF’s Pharma Solutions division is poised to introduce new products and investments at this year's CPHI being held in Barcelona. OSP was lucky enough to catch up with them before the event starting next week.
AstraZeneca’s supplemental new drug application (sNDA) for lead lung cancer drug Tagrisso (Osimertinib) in combination with chemotherapy has been accepted and granted priority review in the US.
In our first podcast interview of 2023, BioPharma Reporter spoke with Dr Sarah Bateup, therapy lead at Clerkenwell Health, about the potential of psychedelic medicine and her work within the psychedelic therapy training space.
The heavy burden on immediate family members with neurodegenerative diseases and their caregivers, was the initial driving force to study pharmacy for Andrea Pfeifer.
Complete clinical trials solution company, Hawthorne Effect, announced today (October 10) it had successfully recruited more than 1,000 patients in 48 states plus Hawaii for a study to qualify the prevalence of valvular heart disease (VHD).
The unique glutamatergic mechanism of action in Newron Pharmaceuticals’ investigational new drug can potentially produce a long-lasting antipsychotic response in patients with TRS, and the benefits will accrue over time.
A new patient-first service that will support sponsors and sites accelerate the development of their therapies has been launched by Innovative Trials yesterday (October 9).
A 15-year partnership between Medidata, a Dassault Systèmes company, and the National Cancer Institute (NCI) has been extended by five years. The NCI is part of the National Institutes of Health.
Calliditas Therapeutics AB announced on Friday (October 5) that the European Medicines Agency (EMA) has issued a positive opinion on the company’s drug, setanaxib in Alport Syndrome (AS).
Former UK Prime Minister, David Cameron, will lead the international efforts of The Oxford-Harrington Rare Disease Centre's new initiative, the therapeutics accelerator.
At DPharm 2023, there was a huge meeting of minds to discuss the latest innovations in clinical trials. Outsourcing Pharma was delighted to have an in-depth discussion with IQVIA’s Elan Josielewski, senior principal and head of operations, patient centered...
Veradigm Inc. and Holmusk have announced the next step in their strategic collaboration helping them move closer to their vision of creating a single source of truth for behavioral health.
Chinese biopharmaceutical company, Hutchmed Limited, has announced today (Friday September 29) that it has taken a step towards bringing a colon and rectum cancer drug to a third market.
Calliditas Therapeutics says it is optimistic about getting full marketing authorization for a drug to treat primary IgA nephropathy (IgAN) after submitting a request to the European Medicines Agency (EMA).
A study to evaluate the effect of seladelparm, a small molecule treatment by CymaBay Therapeutics, Inc. on patients with cirrhosis was announced this month (September 21).
At Advanced Therapies Europe 2023, BioPharma Reporter caught up with ScaleReady's Jenny Stjernberg to discuss her work at the biotech company, her journey from academia to commercial and female representation in the cell and gene therapies industry....
A new approach to discovering targets for Alzheimer’s and other neurodegenerative diseases has been presented by Insilico Medicine with the University of Cambridge, UK.
Patients with a rare and incurable blood cancer, associated with an overproduction of blood cells, will soon have access to a small molecule Novartis treatment.
Mural Health Technologies, Inc. has raised $8 million in seed funding for the growth of its Mural link platform it says is aimed at ‘modernizing the clinical trial experience for both patients and caregivers’.
Built upon seven years of real-world patient journey data, Belong.Life has recently announced the launch of its software as a service (SaaS)-based conversational artificial intelligence (AI) cancer clinical trial matching platform.
This week's woman in science, is Maria Pereira, who leads the Innovation Hub at TISSIUM, a Paris-based medtech startup that develops solutions for tissue reconstruction.